What are you looking for?
A pooled analysis of the phase 3 PULSAR and PHOTON trials found that aflibercept 8 mg, administered at a higher injection volume than aflibercept 2 mg, was not associated with increased long-term intraocular pressure (IOP) or glaucoma-related safety concerns through 96 weeks in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).... ...
Heidelberg Engineering announced FDA clearance of the latest version of its SPECTRALIS® software for multimodal retinal imaging. The release introduces a 250...
Low rates of adverse events among patients with neovascular age-related macular degeneration (nAMD) treated with aflibercept 8 mg were found in a...
Switching patients with neovascular age-related macular degeneration (nAMD) from aflibercept 2 mg to aflibercept 8 mg was associated with modest anatomical improvements...
A pooled analysis of the phase 3 PULSAR and PHOTON trials found that aflibercept 8 mg, administered at a higher injection volume than aflibercept 2 mg, was not associated with...
Heidelberg Engineering announced FDA clearance of the latest version of its SPECTRALIS® software for multimodal retinal imaging. The release introduces a 250 kHz scan speed option for OCT Angiography (OCTA),...
Low rates of adverse events among patients with neovascular age-related macular degeneration (nAMD) treated with aflibercept 8 mg were found in a real-world case series. Researchers retrospectively reviewed safety data...
Switching patients with neovascular age-related macular degeneration (nAMD) from aflibercept 2 mg to aflibercept 8 mg was associated with modest anatomical improvements and stable visual outcomes in a real-world study...
Ocular Therapeutix reported positive topline results from the SOL-1 Phase 3 superiority trial of AXPAXLI (OTX-TKI) versus aflibercept 2 mg in newly diagnosed wet age-related macular degeneration. The pre-specified primary...
Sumit Sharma, MD, of the Cleveland Clinic, spoke with Ophthalmology 360 about a presentation he gave at the Hawaiian Eye meeting on the latest clinical trial updates on the experimental...
In a diabetic screening population, metformin use was associated with a lower risk of developing intermediate age-related macular degeneration (AMD) over 5 years, according to a case-controlled study. Researchers analyzed...
John Chen, MD, PhD, of the Mayo Clinic, talks with Ophthalmology 360 about treatment options for neuromyelitis optica spectrum disorder (NMOSD) and how timely treatment is important to avoid permanent...